The influence of competing-risks setting on the choice of hypothesis test for treatment effect.
There is considerable debate regarding the choice of test for treatment difference in a randomized clinical trial in the presence of competing risks. This question arose in the study of standard and new antiepileptic drugs (SANAD) trial comparing new and standard antiepileptic drugs. This paper provides simulation results for the log-rank test comparing cause-specific hazard rates and Gray's test comparing cause-specific cumulative incidence curves. To inform the analysis of the SANAD trial, competing-risks settings were considered where both events are of interest, events may be negatively correlated, and the degree of correlation may differ in the 2 treatment groups. In settings where there are effects in opposite directions for the 2 event types, a likely situation for the SANAD trial, Gray's test has greater power to detect treatment differences than log-rank analysis. For the epilepsy application, conclusions were qualitatively similar for both log-rank and Gray's tests.
Williamson
P R
PR
Centre for Medical Statistics and Health Evaluation, Shelley's Cottage, Brownlow Street, University of Liverpool, Liverpool L69 3GS, UK. p.r.williamson@liverpool.ac.uk
Kolamunnage-Dona
R
R
Tudur Smith
C
C
D000927:Anticonvulsants / Q000627:therapeutic use; D001699:Biometry; D004827:Epilepsy / Q000188:drug therapy; D006801:Humans; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data*; D016896:Treatment Outcome
D000927:Anticonvulsants